To develop new potent and highly selective MAO-B inhibitors from chalcone-thioethers, eleven chalcones-thioethers were synthesized and their monoamine oxidase (MAO) inhibition, kinetics, reversibility, and cytotoxicity of lead compounds were analyzed. Molecular dynamics were carried out to investigate the interactions. Compound showed potent inhibitory activity against MAO-B, with an IC value of 0.010 µM, followed by , , , and (IC = 0.017, 0.021, 0.023, and 0.026 µM, respectively). Interestingly, had an extremely high selectivity index (SI; 4860) for MAO-B. Reversibility and kinetic experiments showed that and were reversible and competitive inhibitors of MAO-B with K values of 0.0031 ± 0.0013 and 0.011± 0.001 µM, respectively. Both and were non-toxic to Vero cells with IC values of 241.8 and 116.3 µg/mL (i.e., 947.7 and 402.4 µM), respectively, and at these IC values, both significantly reduced reactive oxygen species (ROS) levels. and showed high blood-brain barrier permeabilities in the parallel artificial membrane permeability assay. Molecular dynamics studies were conducted to investigate interactions between and and the active site of MAO-B. Conclusively, and are potent and highly selective MAO-B inhibitors with little toxicity and good ROS scavenging abilities and it is suggested that both are attractive prospective candidates for the treatment of neurological disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623647PMC
http://dx.doi.org/10.3390/ph14111148DOI Listing

Publication Analysis

Top Keywords

potent highly
12
highly selective
12
selective mao-b
8
mao-b inhibitors
8
molecular dynamics
8
investigate interactions
8
mao-b
6
replacement chalcone-ethers
4
chalcone-ethers chalcone-thioethers
4
potent
4

Similar Publications

Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust Antitumor Activity.

J Med Chem

January 2025

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.

Protein arginine methyltransferase 5 (PRMT5), which catalyzes the symmetric dimethylation of arginine residues on target proteins, plays a critical role in gene expression regulation, RNA processing, and signal transduction. Aberrant PRMT5 activity has been implicated in cancers and other diseases, making it a potential therapeutic target. Here, we report the discovery of a methylthioadenosine (MTA) cooperative PRMT5 inhibitor.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Background: γ-Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease (AD). GSMs selectively reduce amyloidogenic long Aβ peptides (e.g.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biosplice Therapeutics, Inc., San Diego, CA, USA.

Background: DYRK1A overexpression, common in neurodegenerative diseases like Alzheimer's (AD), contributes to neurofibrillary tangles via Tau protein hyperphosphorylation and amyloid plaque formation, key AD hallmarks. Therefore, DYRK1A has been regarded as a novel target for neurodegenerative diseases. However, developing DYRK1A selective inhibitors has been a difficult challenge due to the highly conserved ATP-binding site of protein kinases, particularly among the CMGC family.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!